Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$32.95

0.64 (1.98%)

07:12
02/14/19
02/14
07:12
02/14/19
07:12

Alkermes CEO sees 2019 as important year for late-stage pipeline

"Alkermes is defined by our commitment to making medicines that help address critical public health challenges, using our scientific insights to develop medicines that are designed with the real-world needs of patients in mind. Following the positive results of the ALKS 3831 ENLIGHTEN-2 pivotal study and the increasing traction of ARISTADA in the market, we continue to establish our emerging leadership position in the treatment of schizophrenia. 2019 will be an important year for our late-stage pipeline highlighted by the planned submission of the ALKS 3831 New Drug Application and the regulatory review of the recently submitted New Drug Application for diroximel fumarate for multiple sclerosis, with expected action in the fourth quarter. As development activities surrounding our ALKS 4230 immuno-oncology program gain momentum, we expect to have our first indications of ALKS 4230's anti-tumor response activity this year, and we look forward to updating you on our progress," said Richard Pops, CEO of Alkermes.

  • 14

    Feb

ALKS Alkermes
$32.95

0.64 (1.98%)

01/02/19
CANT
01/02/19
NO CHANGE
Target $33
CANT
Neutral
Alkermes lacks meaningful pipeline catalysts in 2019, says Cantor Fitzgerald
Despite being down 60% from its 2018 highs, the risk/reward on Alkermes is adequately reflected in the current stock price, Cantor Fitzgerald analyst Brandon Folkes tells investors in a research note. The analyst says upside to his forecasts and rating could come from ALKS 4230, the company's early immune-oncology candidate. However, he believes near term risk could come from pipeline failures, or Vivitrol and Aristada revenue coming in below consensus estimates. Folkes sees no new meaningful pipeline catalysts in 2019 to get him off the sidelines with respect to shares. As such, he reiterates a Neutral rating on Alkermes with a $33 price target.
01/22/19
JEFF
01/22/19
NO CHANGE
Target $43
JEFF
Hold
Doctors find Alkermes schizophrenia data 'somewhat' meaningful, says Jefferies
Jefferies analyst Biren Amin says his firm performed a second survey of 35 practicing psychiatrists who treat adult schizophrenia following the Enlighten-2 readout from Alkermes. Doctors appear to find the Phase 3 data "somewhat clinically meaningful," with a majority of potential prescriptions for ALKS 3831 converting from olanzapine and other atypicals in 2021, Amin tells investors in a research note. The survey shows that by 2021, about 13% of patients would be prescribed ALKS 3831, with about 50% of its share coming from conversion from other atypicals and 40% coming from olanzapine. The analyst adds that he did not take into account the potential influence of a branded price, which he notes could affect uptake. Amin has a Hold rating on Alkermes with a $43 price target.
02/04/19
STFL
02/04/19
NO CHANGE
STFL
Hold
Alkermes receipt of CRL for 5461 'no surprise,' says Stifel
Stifel analyst Paul Matteis said it came as "no surprise" that the FDA issued a Complete Response Letter to Alkermes related to the company's new drug application for ALKS 5461 for major depressive disorder given the "highly critical advisory committee meeting" that preceded it. Following that "tumultuous adcomm meeting," he had removed any near-term credit for 5461 from his model and Matteis believes that credit for the asset is largely out of other analysts' models as well, he tells investors. While the company is already running a phase 3b trial, which could possibly be supportive of registration, Matteis said he is unsure if the FDA has explicitly signed-off on the design and approach. He keeps a Hold rating on Alkermes shares.
02/07/19
CANT
02/07/19
NO CHANGE
Target $33
CANT
Neutral
Mylan patent challenge on Tecfidera potential positive for Alkermes, says Cantor
Cantor Fitzgerald analyst Brandon Folkes views the institution of Mylan's (MYL) inter partes review challenge of Tecfidera's '514 patent as a potential positive for Alkermes (ALKS). The analyst has assumed Biogen's (BIIB) Tecfidera '514 patent holds through 2028, and thus had ascribed a "more-modest" value to Alkermes' royalty from BIIB098 sales. If Mylan is successful in its IPR challenge, says the analyst, it could provide $4-$7 per share upside to his current Alkermes price target of $33. Biogen reported Tecfidera revenues of $4.3B for 2018, $3.3B of which was generated in the U.S. Alkermes is entitled to a mid-teen royalty on worldwide sales of BIIB098, Folkes tells investors in a research note titled "Giving ALKS a Hall Pass to Support the Away Team This Time." However, he believes the market has discounted the contribution of the BIIB098 royalty to Alkermes, "given the uncertainty about how the product may be included in a Tecfidera life cycle extension given the '514 patent runs to 2028."

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
02/22/19
02/22
12:17
02/22/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
02/22/19
02/22
12:16
02/22/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOX

21st Century Fox

$50.60

0.14 (0.28%)

, FOXA

21st Century Fox

$50.89

0.15 (0.30%)

12:14
02/22/19
02/22
12:14
02/22/19
12:14
Periodicals
Fox removes Jussie Smollett from last two episodes of 'Empire' season, WSJ says »

Producer's of Fox…

FOX

21st Century Fox

$50.60

0.14 (0.28%)

FOXA

21st Century Fox

$50.89

0.15 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

12:13
02/22/19
02/22
12:13
02/22/19
12:13
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks opened with modest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$7.70

-0.26 (-3.27%)

12:05
02/22/19
02/22
12:05
02/22/19
12:05
Periodicals
JAMA editorial says DBV trial results 'not easy to interpret' »

In an editorial published…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$11.15

0.12 (1.09%)

12:05
02/22/19
02/22
12:05
02/22/19
12:05
Options
GameStop call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTN

Union Acquisition Corp

$5.89

-1.44 (-19.65%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Union Acquisition Corp falls -17.3% »

Union Acquisition Corp is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

TDS

Telephone and Data

$32.14

-4.55 (-12.40%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Telephone and Data falls -12.5% »

Telephone and Data is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

DPLO

Diplomat Pharmacy

$7.65

-5.81 (-43.16%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Diplomat Pharmacy falls -42.9% »

Diplomat Pharmacy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 11

    Mar

  • 12

    Mar

PBI

Pitney Bowes

$8.25

1.225 (17.45%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Pitney Bowes rises 17.4% »

Pitney Bowes is up 17.4%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 28

    Mar

SWM

Schweitzer-Mauduit

$41.20

6.51 (18.77%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Schweitzer-Mauduit rises 19.0% »

Schweitzer-Mauduit is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 28

    Mar

W

Wayfair

$153.23

36.09 (30.81%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Wayfair rises 30.9% »

Wayfair is up 30.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 03

    Mar

CAG

Conagra Brands

$23.13

-0.95 (-3.95%)

11:55
02/22/19
02/22
11:55
02/22/19
11:55
Options
ConAgra put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
02/22/19
02/22
11:55
02/22/19
11:55
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

11:55
02/22/19
02/22
11:55
02/22/19
11:55
Conference/Events
William Blair medical tech analyst to hold a luncheon »

Medical Technology &…

TKR

Timken

$43.82

0.41 (0.94%)

11:51
02/22/19
02/22
11:51
02/22/19
11:51
Conference/Events
Timken management to meet with KeyBanc »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

KPTI

Karyopharm

$8.97

0.01 (0.11%)

11:50
02/22/19
02/22
11:50
02/22/19
11:50
Recommendations
Karyopharm analyst commentary  »

H.C. Wainwright sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

JEC

Jacobs Engineering

$74.22

0.45 (0.61%)

11:48
02/22/19
02/22
11:48
02/22/19
11:48
Conference/Events
Jacobs Engineering management to meet with KeyBanc »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 12

    Mar

TCDA

Tricida

$23.11

0.84 (3.77%)

11:46
02/22/19
02/22
11:46
02/22/19
11:46
Initiation
Tricida initiated  »

Tricida initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$109.87

-1.89 (-1.69%)

11:45
02/22/19
02/22
11:45
02/22/19
11:45
Options
UPS call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

11:45
02/22/19
02/22
11:45
02/22/19
11:45
General news
More from Williams: the Phillips Curve needs to be taken seriously »

More from Williams: the…

OCUL

Ocular Therapeutix

$4.22

0.61 (16.90%)

11:37
02/22/19
02/22
11:37
02/22/19
11:37
Hot Stocks
Ocular Therapeutix higher after pricing $37.5M in convertible notes »

Shares of Ocular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:35
02/22/19
02/22
11:35
02/22/19
11:35
General news
The Fed's Monetary Policy Report »

The Fed's Monetary…

AXNX

Axonics

$21.65

-0.85 (-3.78%)

11:33
02/22/19
02/22
11:33
02/22/19
11:33
Hot Stocks
Axonics granted expanded CE mark label approval for Axonics r-SNM System »

Axonics Modulation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

  • 05

    Mar

EA

Electronic Arts

$95.01

-1.825 (-1.88%)

11:30
02/22/19
02/22
11:30
02/22/19
11:30
Options
Buyer pays $3.3M for EA upside calls as shares drop 2% »

Buyer pays $3.3M for EA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.